Sodium-Glucose cotransporter 2 Inhibition with Dapagliflozin Ameliorates Extracellular Volume Expansion in Diabetic Kidney Disease Patients

Background: Sodium-glucose cotransporter (SGLT) 2 inhibitors, a new class of antidiabetic drugs, have diuretic properties, but their effects on urinary Na excretion and the fluid status have not been fully evaluated. Methods: Diabetic kidney disease (DKD) patients with fluid retention were enrolled in this study. The SGLT2 inhibitor dapagliflozin was administered in addition to conventional treatment. Blood and 24-h urine samples were collected before dapagliflozin dosing on day 0 and afterwards on days 2 and 7. The fluid volume was measured using a bioimpedance analysis device on days 0 and 7. The paired t-test or repeated-measure ANOVA was used to compare variables. Stepwise multivariate regression analysis was used to assess associations between independent variables. Results: The body weight, diastolic blood pressure and brain natriuretic peptide significantly decreased, and serum albumin and urinary glucose excretion significantly increased over 1 week. The urine volume increased by 18.7% ± 13.4% (p=0.251), urinary Na excretion increased by 43.0% ± 20.4% (p=0.035) and urinary Cl excretion incread by 39.2% ± 19.7% (p=0.051) on day 2 compared with day 0, but these parameters returned to the baseline level on day 7. Stepwise multivariate regression analysis showed that HbA1c (p=0.031) and urinary glucose excretion (p=0.018) were independent determinants of changes in urinary Na excretion on day 2. Dapagliflozin significantly decreased the intracellular water (ICW) (6.2% ± 1.4%, p=0.001), extracellular water (ECW) (8.5% ± 2.0%, p=0.001) and total body water (TBW) (7.2% ± 1.6%, p=0.001) between days 0 and 7. The ECW/TBW, which reflects the extracellular volume expansion, significantly decreased from 0.424 ± 0.007 to 0.418 ± 0.006 (p=0.020). Conclusions: SGLT2 inhibition with dapagliflozin increases transient urinary Na excretion, and decreased body fluid volume with the amelioration of extracellular volume expansion in DKD patients. This effect of SGLT2 inhibition may lead to a novel therapeutic strategy for body fluid control, especially in patients with increased extracellular water.